Ascendia’s executive leadership team has been attending the JP Morgan Healthcare Conference for over 10 years now. The annual events that comprise the conference have become a place where C-suite executives gather, scientists meet to discuss the year’s findings, and the industry does a “reset” as the market recapitalizes. Essentially, it is where business and science meet to “lock and load” for the upcoming year.
The 2024 conference, to be held January 8-11 in San Francisco, will be no different, and is why Ascendia is once again participating. JP Morgan Healthcare Conference week is kind of a catalyst, as many conversations start that week and continue throughout the year. For instance, it was during last year’s conference that meetings were held in which a lot of the cell and gene therapy discussions began. Those waves of interest sort of carried themselves throughout the rest of 2023 within the industry.
Part of BioTech Showcase
The Ascendia team is once again pleased to announce that we will be taking part in the Biotech Showcase, happening concurrently alongside the JP Morgan Healthcare Conference. This is a one-on-one meeting event where our leadership team is able to take advantage of having access to existing clients or companies we have worked with, while looking for new opportunities with other organizations and potential partners.
We also look forward to meeting with many analysts in San Francisco who continue to follow us and track Ascendia’s continued strong performance. Our word to them during last year’s Showcase was a consistent message – what makes Ascendia perfectly poised to benefit for the advancements in 2023 was the development of our capabilities and skillsets.
…and those analysts were exactly right.
Building Off A Strong Year
2023 was a banner year for Ascendia, with a number of advances that we implemented and employed for our customers. For example, we introduced our fourth proprietary nanotechnology – LipidSol. Composed of lipid-based assemblies, the lipid nanoparticle (LNP) technology aids drug development teams encapsulate small and large molecules, as well as biologics in nanoparticle structures. Ascendia also expanded its sterile/non-sterile headquarters by 60,000 square feet, and doubled the number of employees, which is all part of Ascendia’s three-year CAGR of 55%.
Evident by these advances, we met all of the analysts’ expectations and continue to exceed them now. Our expanded footprint allows for additional suites to manage all the extra projects we are working on. . We grew our headcount to accomodate the needs of our new customers, as well as the ongoing needs of our existing customers.
While others in the industry sell capabilities. Ascendia sells Solutions, having proven we are capable of doing such, with confidence and consistency. This shows our command of Generally Recognized As Safe (GRAS) materials and components, along with our ability to traverse multiple dosage forms in sterile and non-sterile, oral, injectables, ophthalmic suspensions, and emulsions that are very difficult to develop. These are robust formulations that can be manufactured reliably and consistently, through the first phase of testing. All of the things we have been doing have us perfectly positioned for years ahead, as Ascendia and our colleagues continue to embrace our BEST (Brilliant technologies, Excellent services, Superior quality and Trust) philosophy and name us Partner of Choice.
Meet With Us
Contact us to schedule a meeting in San Francsco. We look forward to seeing you there.